公开(公告)号：WO2019104154A1

公开(公告)日：2019-05-31

申请号：PCT/US2018/062229

申请日：2018-11-21

Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Inventor： PAREKKADAN, Biju ,  AIJAZ, Ayesha

IPC: C12M1/12 ,  C12N5/00

CPC classification number: C12M25/16 ,  C12N5/0012 ,  C12N5/0663 ,  C12N2533/30

Abstract: Systems and methods for growing cells are provided. A capsule for growing or storing cells includes a shell defining an interior compartment and a substrate for cell attachment located within the compartment. The substrate comprises a polymer and one or more adhesion molecules. The substrate for cell attachment can be an inner surface of the shell and/or a hydrogel disposed within the interior compartment. The capsule can further include a cell, such as a stem cell, adhered to the substrate

公开(公告)号：WO2019053729A1

公开(公告)日：2019-03-21

申请号：PCT/IL2018/051055

申请日：2018-09-17

Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED

Inventor： ROSENMANN, Hanna

IPC: A61K9/00 ,  A61K47/02 ,  A61K9/08 ,  A61K38/18 ,  A61P31/00 ,  A61K39/395 ,  C07K16/24 ,  A61P25/28

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K35/28 ,  A61K35/51 ,  A61K38/1841 ,  A61K38/185 ,  A61K47/02 ,  A61P25/28 ,  C12N5/0619 ,  C12N5/0648 ,  C12N5/0663 ,  C12N2500/14 ,  C12N2500/16 ,  C12N2500/84 ,  C12N2502/1358

Abstract: The present disclosure provides an enriched artificial cerebrospinal fluid (EA-CSF) composition comprising: an electrolyte containing solution comprising at least one electrolyte selected from the group consisting of sodium ion, potassium ion, calcium ion, magnesium ion, phosphor ion, chloride ion and carbonate ion; and at least one neuroprotective factor. Also provided by the present disclosure are methods for producing the EA-CSF as well as methods of using the same for treating diseases, specifically, neurological diseases.

公开(公告)号：WO2019045649A1

公开(公告)日：2019-03-07

申请号：PCT/SG2018/050438

申请日：2018-08-29

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： LIAU, Brian ,  RAGHOTHAMAN, Deepak ,  OH, Steve

IPC: C12N5/0775

CPC classification number: C12N5/0663

Abstract: Methods of enriching non-senescent mesenchymal stem cells (MSCs) and methods of performing quality control for non-senescent MSCs are disclosed. The methods comprise contacting a sample comprising MSCs with a probe (specifically peanut agglutinin, PNA) that binds to a glycan (specifically glycan T-antigen) expressed on the surface of MSCs, with the separation or determination of non-senescent MSCs from senescent MSCs based on a difference in expression of the glycan at the cell surface, i.e. the non-senescent MSCs express more of the glycan than senescent MSCs. A high amount of non-senescent MSCs is indicative of a sample of acceptable quality.

公开(公告)号：WO2017184674A1

公开(公告)日：2017-10-26

申请号：PCT/US2017/028266

申请日：2017-04-19

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： CHURCH, George M. ,  BYRNE, Susan M.

IPC: C12N15/90 ,  C12N15/85 ,  C12N9/22

CPC classification number: C12N15/907 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0663 ,  C12N5/0696 ,  C12N9/22 ,  C12N2310/20 ,  C12N2740/16043

Abstract: Inhibiting p53 or Bax can be used to improve nuclease-mediated gene targeting frequencies in stem cells. This inhibition can be achieved, e.g., by overexpression of anti-apoptosis proteins or by silencing or reducing p53 or Bax expression. This technique can be used in conjunction with other rapidly developing CRISPR technologies, including improvements in specificity, other types of nucleases, and further enrichment, screening, and selection schemes, to expand the use of stem cells in experimental studies and tissue engineering for therapeutic purposes.

Abstract translation: 抑制p53或Bax可用于改善干细胞中核酸酶介导的基因靶向频率。 这种抑制可以通过例如抗凋亡蛋白的过表达或通过沉默或减少p53或Bax表达来实现。 这项技术可以与其他快速发展的CRISPR技术结合使用，包括提高特异性，其他类型的核酸酶以及进一步的富集，筛选和选择方案，扩大干细胞在实验研究和组织工程学中的应用，以达到治疗目的

公开(公告)号：WO2017125917A1

公开(公告)日：2017-07-27

申请号：PCT/IL2017/050058

申请日：2017-01-17

Applicant: AMORPHICAL LTD.

Inventor： BEN, Yosef ,  SHAHAR, Abraham ,  ARAV, Amir

IPC: A61K33/06 ,  A61K33/10 ,  A61K31/66 ,  C12N5/00 ,  C12N5/04 ,  C12N5/073

CPC classification number: C12N5/0018 ,  C12N5/0604 ,  C12N5/0609 ,  C12N5/061 ,  C12N5/0619 ,  C12N5/0658 ,  C12N5/0663 ,  C12N2500/14

Abstract: Stabilized amorphous calcium carbonate (ACC) as a supplement of cell culture media and the cell culture medium supplements comprising stabilized ACC are provided. In particular the stabilized ACC is useful for enhancing the growth of cell and tissue cultures, gametes and embryos in vitro.

Abstract translation: 提供稳定的无定形碳酸钙（ACC）作为细胞培养基的补充物和包含稳定的ACC的细胞培养基补充物。 特别是稳定的ACC可用于增强细胞和组织培养物，配子和胚胎的体外生长。

公开(公告)号：WO2017021535A1

公开(公告)日：2017-02-09

申请号：PCT/EP2016/068767

申请日：2016-08-05

Applicant: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD ,  UNIVERSIDAD PABLO DE OLAVIDE ,  NEW BIOTECHNIC, S.A.

Inventor： SORIA ESCOMS, Bernat ,  HMADCHA, Abdelkrim ,  TEJEDO HUAMAN, Juan Rigoberto ,  BEDOYA BERGUA, Francisco, Javier

IPC: C12N5/00

CPC classification number: C12N5/0667 ,  C12N5/0663 ,  C12N2501/03

Abstract: The invention provides new culture media and methods for hPCs' isolation and expansion using said media, which provide significant advantages over known culture media and isolation and expansion methods. These culture media are characterized by the presence of a nitric oxide donor. In addition the culture media of the invention are preferably serum supplemented or serum-free.

Abstract translation: 本发明提供使用所述培养基的hPCs分离和扩增的新的培养基和方法，其提供了超过已知培养基和分离和扩增方法的显着优点。 这些培养基的特征在于存在一氧化氮供体。 此外，本发明的培养基优选为补充血清或​​不含血清。

公开(公告)号：WO2017019590A1

公开(公告)日：2017-02-02

申请号：PCT/US2016/043839

申请日：2016-07-25

Applicant: ROOSTERBIO, INC.

Inventor： LOCK, Lye Theng ,  ROWLEY, Jonathan Allen

IPC: C12N5/00 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/0797

CPC classification number: C12N5/0663 ,  C12N5/0075 ,  C12N2500/62 ,  C12N2531/00

Abstract: Disclosed herein are compositions and methods involving stem cells biopreserved on microcarriers, which can be thawed and expanded, all while maintaining their key attributes, such as their proliferative capacity, identity, functionality, and potency. Disclosed is a method for generating microcarriers-seeded-stem cells, as well as a post biopreservation procedure for thawing and inoculating bioreactors to achieve a rapid and scalable stem cells expansion.

Abstract translation: 本文公开的是涉及在微载体上生物保护的干细胞的组合物和方法，其可以融化和扩增，同时保持其关键属性，例如其增殖能力，身份，功能和效力。 公开了一种用于产生微载体 - 种子干细胞的方法，以及用于解冻和接种生物反应器以实现快速和可扩展的干细胞扩增的后生物保存程序。

公开(公告)号：WO2017010100A1

公开(公告)日：2017-01-19

申请号：PCT/JP2016/003319

申请日：2016-07-14

Applicant: ダイキン工業株式会社 ,  株式会社大塚製薬工場

Inventor： 樋口　達也 ,  駒澤　梢 ,  茂原　美子 ,  傳寶　孝之 ,  西村　益浩

IPC: C12M3/00

CPC classification number: C12M23/20 ,  A61K35/28 ,  C09D127/18 ,  C09D127/20 ,  C09D129/10 ,  C12M23/14 ,  C12N5/0663

Abstract: －ＣＦ ３ の末端基を少なくとも一部含むフッ素樹脂素材で哺乳動物細胞と接触する表面が形成されている容器、あるいは、フッ素樹脂における非フッ素化基末端と－ＣＦ ２ Ｈ基末端とを合計した数が炭素１×１０ ６ 当たり７０個以下であるフッ素樹脂材で哺乳動物細胞と接触する表面が形成されている容器を用いて哺乳動物細胞を投与したり、かかる容器内で、哺乳動物細胞を保存又は培養すると、容器内面への細胞接着や細胞生存率低下を効果的に抑制できる。したがって、これらの容器を使用することにより、高濃度でかつ生細胞の割合が高い哺乳動物細胞含有液を投与、保存、又は調製することが可能であり、哺乳動物細胞含有液（懸濁液）を用いた再生医療に資するものである。

Abstract translation: 当施用哺乳动物细胞或将哺乳动物细胞储存或培养在容器中时，可以通过使用以下方法有效地抑制对容器内表面的细胞粘附和细胞活力的降低：其中与哺乳动物细胞接触的表面是 由包含至少一些-CF 3端基的氟树脂材料形成; 或其中与哺乳动物细胞接触的表面由氟树脂材料形成的容器，其中氟树脂中的非氟端基和-CF 2端基的总数不超过每1×10 6个碳的70个。 使用这样的容器使得可以高浓度地施用，储存或制备含有哺乳动物细胞的液体并具有大量的活细胞，并且有助于使用含有哺乳动物细胞的液体（悬浮液）的再生药物。

公开(公告)号：WO2016200888A1

公开(公告)日：2016-12-15

申请号：PCT/US2016/036371

申请日：2016-06-08

Applicant: CORNING INCORPORATED

Inventor： CARACCI, Stephen Joseph ,  HENRY, David ,  WALERACK, Corinne ,  ZHOU, Yue

IPC: C12N5/00 ,  C12N5/0775 ,  C08L5/00

CPC classification number: C12N5/0075 ,  C08L5/00 ,  C12N5/0663 ,  C12N5/0686 ,  C12N5/0688 ,  C12N2531/00 ,  C12N2533/18 ,  C12N2533/70

Abstract: A cell culture article is provided. The cell culture substrate includes a polygalacturonic acid compound selected from at least one of: pectic acid or salts thereof, and partially esterified pectic acid having a degree of esterification from 1 to 40 mol% or salts thereof. The polygalacturonic acid compound is crosslinked with a divalent cation and the divalent cation concentration ranges from 0.5 to 2 g/l of the substrate.

Abstract translation: 提供细胞培养物品。 细胞培养基质包括选自以下的至少一种的聚半乳糖醛酸化合物：果胶酸或其盐，酯化度为1〜40摩尔％的部分酯化果胶酸或其盐。 聚半乳糖醛酸化合物与二价阳离子交联，二价阳离子浓度范围为0.5〜2g / l的底物。

公开(公告)号：WO2016187451A1

公开(公告)日：2016-11-24

申请号：PCT/US2016/033320

申请日：2016-05-19

Applicant: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.

Inventor： WANG, Jiwu ,  NI, Yuhui

IPC: A01N63/00 ,  C12N5/02 ,  C12N5/071

CPC classification number: C12N5/0696 ,  C12N5/0619 ,  C12N5/0622 ,  C12N5/0653 ,  C12N5/0657 ,  C12N5/0658 ,  C12N5/0663 ,  C12N5/067 ,  C12N5/0676 ,  C12N5/0688 ,  C12N2500/38 ,  C12N2500/62 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/39 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/45 ,  C12N2533/32 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/90 ,  C12N2539/00

Abstract: Method of changing the pluripotent state or progenitor state of stem cells or progenitor cells towards a specific lineage or tissue cell type, comprising at least one of: generate cells expressing critical cell fate genes (collectively referred as stem cells), including key cell fate factors and fusions between conventional transcription factors (TFs) with transactivation domains, optimized for directing stem cells towards different types of cells; introducing these factors as synthetic messenger RNA (mRNA) into cultured pluripotent stem cells at the preferred density by methods that result in appropriate levels of transgene expression; maintaining cell under optimized conditions to result in high efficiency of specific differentiation.

Abstract translation: 将干细胞或祖细胞的多能状态或祖细胞状态改变为特定谱系或组织细胞类型的方法，包括至少一种：产生表达关键细胞命运基因（统称为干细胞）的细胞，包括关键细胞命运因子 和常规转录因子（TFs）与反式激活结构域之间的融合，优化用于将干细胞导向不同类型的细胞; 通过导致适当水平的转基因表达的方法，将这些因子作为合成信使RNA（mRNA）以优选的密度引入培养的多能干细胞中; 在优化的条件下保持细胞，从而导致特异性分化的高效率。